Identification

Name
Capromab pendetide
Accession Number
DB00089  (BTD00080, BIOD00080)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Capromab is used to image the extent of prostate cancer.

Protein structure
Db00089
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • (111In)-Capromab pendetide
  • Indium (111In) capromab pendetide
  • Indium 111 Capromab Pendetide
  • Indium In 111 capromab pendetide
External IDs
CYT-356 / Cytogen 356
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProstaScint Kit for the Preparation of Indium In 111 Capromab PendetideKitJazz Pharmaceuticals1996-10-28Not applicableUs
International/Other Brands
ProstaScint (Cytogen Corp.)
Categories
UNII
BDO5072GRX
CAS number
145464-28-4

Pharmacology

Indication

For diagnosis of prostate cancer and detection of intra-pelvic metastases.

Structured Indications
Pharmacodynamics

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.

Mechanism of action

Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.

TargetActionsOrganism
AGlutamate carboxypeptidase 2
other/unknown
Human
Absorption
Not Available
Volume of distribution
  • 4 ± 2.1 L
Protein binding
Not Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production

Route of elimination

Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.

Half life
Not Available
Clearance
  • 42 +/- 22 mL/hr
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
19-norandrostenedione19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental, Illicit
5-androstenedione5-androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental, Illicit
AlclometasoneAlclometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
AldosteroneAldosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental, Investigational
AmcinonideAmcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
AndrostenedioneAndrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental, Illicit
AnecortaveAnecortave may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
anecortave acetateanecortave acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
AtamestaneAtamestane may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Capromab pendetide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
BetamethasoneBetamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
BicalutamideBicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
BudesonideBudesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
BuserelinBuserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
ChlormadinoneChlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
ChlorotrianiseneChlorotrianisene may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational, Withdrawn
CiclesonideCiclesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
ClobetasolClobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
Clobetasol propionateClobetasol propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
ClobetasoneClobetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
ClocortoloneClocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide.Approved
Conjugated estrogensConjugated estrogens may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
CorticosteroneCorticosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
Cortisone acetateCortisone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide.Approved
Cyproterone acetateCyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
DaidzeinDaidzein may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
DanazolDanazol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
DeflazacortDeflazacort may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
DeslorelinDeslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational, Vet Approved
DesonideDesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
DesoximetasoneDesoximetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental, Vet Approved
DexamethasoneDexamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Vet Approved
DienestrolDienestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
DiethylstilbestrolDiethylstilbestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
DiflorasoneDiflorasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
DifluocortoloneDifluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
DifluprednateDifluprednate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
EpimestrolEpimestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
EquileninEquilenin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
EquilinEquilin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
EquolEquol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
EstradiolEstradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational, Vet Approved
EstriolEstriol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
EstroneEstrone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Estrone sulfateEstrone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Ethinyl EstradiolEthinyl Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
fluasteronefluasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
FludrocortisoneFludrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
FlumethasoneFlumethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
FlunisolideFlunisolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
FluocortoloneFluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Withdrawn
FluorometholoneFluorometholone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
FluprednideneFluprednidene may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Withdrawn
FluprednisoloneFluprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
FlurandrenolideFlurandrenolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
FlutamideFlutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Fluticasone furoateFluticasone furoate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Fluticasone propionateFluticasone propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
FormestaneFormestane may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational, Withdrawn
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Capromab pendetide.Investigational
GenisteinGenistein may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
GestrinoneGestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Capromab pendetide.Investigational
GoserelinGoserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
HalcinonideHalcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational, Withdrawn
HE3286HE3286 may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Capromab pendetide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Capromab pendetide.Approved, Withdrawn
HexestrolHexestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Withdrawn
HistrelinHistrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
HydrocortisoneHydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Capromab pendetide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Capromab pendetide.Investigational
IstaroximeIstaroxime may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
LeuprolideLeuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
LiarozoleLiarozole may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
LoteprednolLoteprednol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
ME-609ME-609 may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
MedrysoneMedrysone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
MelengestrolMelengestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Vet Approved
MestranolMestranol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
MethallenestrilMethallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
MethylprednisoloneMethylprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
MometasoneMometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
MoxestrolMoxestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental
NafarelinNafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
NCX 1022NCX 1022 may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
NilutamideNilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Oleoyl-estroneOleoyl-estrone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
ParamethasoneParamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Polyestradiol phosphatePolyestradiol phosphate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
PrasteronePrasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
PrednicarbatePrednicarbate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
PrednisolonePrednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
PrednisonePrednisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
PregnenolonePregnenolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Experimental, Investigational
PromestrienePromestriene may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
QuinestrolQuinestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Capromab pendetide.Approved
RimexoloneRimexolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Capromab pendetide.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Capromab pendetide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Capromab pendetide.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Capromab pendetide.Approved
SecoisolariciresinolSecoisolariciresinol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Capromab pendetide.Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Capromab pendetide.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Capromab pendetide.Investigational
TiboloneTibolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Investigational
TixocortolTixocortol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
TriamcinoloneTriamcinolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
TriptorelinTriptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved, Vet Approved
UlobetasolUlobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Capromab pendetide.Approved
ZeranolZeranol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Vet Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Capromab pendetide.Approved
Food Interactions
Not Available

References

General References
  1. Link [Link]
  2. Link [Link]
  3. Link [Link]
External Links
PubChem Substance
46506263
ChEMBL
CHEMBL2108285
Therapeutic Targets Database
DAP001049
PharmGKB
PA164745489
Wikipedia
Indium_(111In)_capromab_pendetide
ATC Codes
V09IB04 — Indium (111in) capromab pendetide
FDA label
Download (1.65 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Kit
Prices
Unit descriptionCostUnit
Prostascint kit1584.0USD kit
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other/unknown
General Function
Tetrahydrofolyl-poly(glutamate) polymer binding
Specific Function
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
Gene Name
FOLH1
Uniprot ID
Q04609
Uniprot Name
Glutamate carboxypeptidase 2
Molecular Weight
84330.015 Da
References
  1. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [PubMed:11016653]
  2. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [PubMed:15882479]
  3. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [PubMed:9508077]
  4. Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [PubMed:9792131]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on November 06, 2017 06:43